Is ANNX or CHRS more profitable?

Annexon has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Annexon's return on equity of -101.19% beat Coherus Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Coherus Oncology -259.41% -222.75% -52.11%

Does the media prefer ANNX or CHRS?

In the previous week, Coherus Oncology had 3 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Coherus Oncology and 3 mentions for Annexon. Annexon's average media sentiment score of 0.71 beat Coherus Oncology's score of 0.16 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor ABUS or CHRS?

In the previous week, Coherus Oncology had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Coherus Oncology and 1 mentions for Arbutus Biopharma. Coherus Oncology's average media sentiment score of 0.16 beat Arbutus Biopharma's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, CHRS or ODTX?

Coherus Oncology has higher revenue and earnings than Odyssey Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coherus Oncology $42.17M 4.65 $168.02M -$1.03 N/A Odyssey Therapeutics N/A N/A N/A N/A N/A

Does the media favor CHRS or ODTX?

In the previous week, Coherus Oncology and Coherus Oncology both had 6 articles in the media. Odyssey Therapeutics' average media sentiment score of 0.45 beat Coherus Oncology's score of 0.16 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Odyssey Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GERN or CHRS more profitable?

Geron has a net margin of -34.17% compared to Coherus Oncology's net margin of -259.41%. Geron's return on equity of -24.48% beat Coherus Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Geron -34.17% -24.48% -10.30% Coherus Oncology -259.41% -222.75% -52.11%

Does the media prefer GERN or CHRS?

In the previous week, Geron had 16 more articles in the media than Coherus Oncology. MarketBeat recorded 22 mentions for Geron and 6 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.16 beat Geron's score of -0.16 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CHRS or KURA?

In the previous week, Coherus Oncology had 2 more articles in the media than Kura Oncology. MarketBeat recorded 6 mentions for Coherus Oncology and 4 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.69 beat Coherus Oncology's score of 0.16 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Coherus Oncology (CHRS) Competitors

$1.27 +0.01 (+0.40%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.32 +0.05 (+3.94%)

As of 08/7/2026 07:34 PM Eastern

Compare

CHRS vs. ANNX, ABUS, ODTX, GERN, and KURA

Should you buy Coherus Oncology stock or one of its competitors? MarketBeat compares Coherus Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coherus Oncology include Annexon (ANNX), Arbutus Biopharma (ABUS), Odyssey Therapeutics (ODTX), Geron (GERN), and Kura Oncology (KURA). These companies are all part of the "biotechnology" industry.

How does Coherus Oncology compare to Annexon?

Annexon (NASDAQ:ANNX) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Annexon currently has a consensus target price of $15.33, suggesting a potential upside of 183.43%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 582.41%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Coherus Oncology	$42.17M	4.65	$168.02M	-$1.03	N/A

In the previous week, Coherus Oncology had 3 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Coherus Oncology and 3 mentions for Annexon. Annexon's average media sentiment score of 0.71 beat Coherus Oncology's score of 0.16 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

72.8% of Coherus Oncology shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 7.2% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Annexon has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Annexon's return on equity of -101.19% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Annexon has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Summary

Coherus Oncology beats Annexon on 9 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Coherus Oncology had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Coherus Oncology and 1 mentions for Arbutus Biopharma. Coherus Oncology's average media sentiment score of 0.16 beat Arbutus Biopharma's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Coherus Oncology has higher revenue and earnings than Arbutus Biopharma. Coherus Oncology is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	64.96	-$33.50M	$0.83	5.58
Coherus Oncology	$42.17M	4.65	$168.02M	-$1.03	N/A

Arbutus Biopharma has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Coherus Oncology's net margin of -259.41%. Arbutus Biopharma's return on equity of 129.32% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Arbutus Biopharma currently has a consensus target price of $5.00, suggesting a potential upside of 7.99%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 582.41%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Coherus Oncology beats Arbutus Biopharma on 9 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Odyssey Therapeutics?

Coherus Oncology (NASDAQ:CHRS) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Coherus Oncology currently has a consensus price target of $8.67, suggesting a potential upside of 582.41%. Odyssey Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 55.88%. Given Coherus Oncology's higher possible upside, equities research analysts plainly believe Coherus Oncology is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Odyssey Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Coherus Oncology and Coherus Oncology both had 6 articles in the media. Odyssey Therapeutics' average media sentiment score of 0.45 beat Coherus Oncology's score of 0.16 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Odyssey Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Odyssey Therapeutics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Odyssey Therapeutics' return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Odyssey Therapeutics	N/A	N/A	N/A

72.8% of Coherus Oncology shares are held by institutional investors. 7.2% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Coherus Oncology has higher revenue and earnings than Odyssey Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	4.65	$168.02M	-$1.03	N/A
Odyssey Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Odyssey Therapeutics beats Coherus Oncology on 6 of the 10 factors compared between the two stocks.

How does Coherus Oncology compare to Geron?

Geron (NASDAQ:GERN) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

In the previous week, Geron had 16 more articles in the media than Coherus Oncology. MarketBeat recorded 22 mentions for Geron and 6 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.16 beat Geron's score of -0.16 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Geron currently has a consensus target price of $4.00, suggesting a potential upside of 170.27%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 582.41%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Geron has a net margin of -34.17% compared to Coherus Oncology's net margin of -259.41%. Geron's return on equity of -24.48% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Geron has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

73.7% of Geron shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 7.2% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Coherus Oncology has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	5.17	-$83.50M	-$0.11	N/A
Coherus Oncology	$42.17M	4.65	$168.02M	-$1.03	N/A

Summary

Geron and Coherus Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Kura Oncology?

Coherus Oncology (NASDAQ:CHRS) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Coherus Oncology has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Coherus Oncology has a net margin of -259.41% compared to Kura Oncology's net margin of -411.19%. Kura Oncology's return on equity of -141.95% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Kura Oncology	-411.19%	-141.95%	-43.28%

Coherus Oncology has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	4.65	$168.02M	-$1.03	N/A
Kura Oncology	$67.48M	12.59	-$278.67M	-$3.35	N/A

Coherus Oncology currently has a consensus price target of $8.67, indicating a potential upside of 582.41%. Kura Oncology has a consensus price target of $25.46, indicating a potential upside of 166.06%. Given Coherus Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Coherus Oncology is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

72.8% of Coherus Oncology shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Coherus Oncology had 2 more articles in the media than Kura Oncology. MarketBeat recorded 6 mentions for Coherus Oncology and 4 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.69 beat Coherus Oncology's score of 0.16 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Coherus Oncology beats Kura Oncology on 9 of the 16 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$195.44M	$3.62B	$6.93B	$12.87B
Dividend Yield	N/A	3.77%	2.59%	9.91%
P/E Ratio	-1.23	9.03	271.11	25.24
Price / Sales	4.65	1,274.65	598.27	98.58
Price / Cash	N/A	98.58	71.46	49.72
Price / Book	3.26	18.10	13.25	6.22
Net Income	$168.02M	-$13.25M	$3.45B	$342.66M
7 Day Performance	-9.93%	6.24%	4.65%	4.41%
1 Month Performance	-23.03%	-2.70%	-0.80%	-0.28%
1 Year Performance	54.88%	61.17%	76.93%	22.60%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	2.8216 of 5 stars	$1.27 +0.4%	$8.67 +582.4%	+43.7%	$195.44M	$42.17M	N/A	330	News Coverage Earnings Report High Trading Volume
ANNX Annexon	3.624 of 5 stars	$5.43 +3.3%	$15.33 +182.6%	+128.3%	$887.36M	N/A	N/A	60	Positive News Upcoming Earnings Gap Up
ABUS Arbutus Biopharma	1.0931 of 5 stars	$4.47 +2.6%	$5.00 +11.8%	+36.2%	$879.05M	$14.08M	5.36	90	Positive News
ODTX Odyssey Therapeutics	3.8498 of 5 stars	$18.19 +0.3%	$32.00 +75.9%	N/A	$873.68M	$1.06M	N/A	N/A	News Coverage Earnings Report Analyst Forecast
GERN Geron	2.1782 of 5 stars	$1.35 +5.1%	$4.00 +197.4%	+13.8%	$862.85M	$196.12M	N/A	70	Trending News Earnings Report Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. ANNX, ABUS, ODTX, GERN, and KURA

How does Coherus Oncology compare to Annexon?

Summary

How does Coherus Oncology compare to Arbutus Biopharma?

Summary

How does Coherus Oncology compare to Odyssey Therapeutics?

Summary

How does Coherus Oncology compare to Geron?

Summary

How does Coherus Oncology compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. ANNX, ABUS, ODTX, GERN, and KURA

How does Coherus Oncology compare to Annexon?

Do analysts recommend ANNX or CHRS?

Which has higher valuation and earnings, ANNX or CHRS?

Does the media prefer ANNX or CHRS?

Do institutionals & insiders have more ownership in ANNX or CHRS?

Is ANNX or CHRS more profitable?

Which has more volatility & risk, ANNX or CHRS?

Summary

How does Coherus Oncology compare to Arbutus Biopharma?

Do insiders & institutionals hold more shares of ABUS or CHRS?

Does the media favor ABUS or CHRS?

Which has stronger valuation and earnings, ABUS or CHRS?

Which has more risk & volatility, ABUS or CHRS?

Is ABUS or CHRS more profitable?

Do analysts prefer ABUS or CHRS?

Summary

How does Coherus Oncology compare to Odyssey Therapeutics?

Do analysts rate CHRS or ODTX?

Does the media favor CHRS or ODTX?

Is CHRS or ODTX more profitable?

Do insiders and institutionals believe in CHRS or ODTX?

Which has preferable valuation & earnings, CHRS or ODTX?

Summary

How does Coherus Oncology compare to Geron?

Does the media prefer GERN or CHRS?

Do analysts rate GERN or CHRS?

Is GERN or CHRS more profitable?

Which has more volatility and risk, GERN or CHRS?

Do institutionals & insiders believe in GERN or CHRS?

Which has stronger earnings and valuation, GERN or CHRS?

Summary

How does Coherus Oncology compare to Kura Oncology?

Which has more risk and volatility, CHRS or KURA?

Is CHRS or KURA more profitable?

Which has preferable earnings and valuation, CHRS or KURA?

Do analysts recommend CHRS or KURA?

Do insiders & institutionals have more ownership in CHRS or KURA?

Does the media refer more to CHRS or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools